Optogenetic technologies in translational cancer research

• Published in: Biotechnology advances 2022-11, Vol.60, p.108005-108005, Article 108005
• Main Authors: Malogolovkin, Alexander, Egorov, Alexander D., Karabelsky, Alexander, Ivanov, Roman A., Verkhusha, Vladislav V.
• Format: Article
• Language: English
• Subjects: CAR-T; CRISPR; Immunotherapy; Oncolytics; Optobodies; Tumor; Viral vector
• ISSN: 0734-9750; 1873-1899
• DOI: 10.1016/j.biotechadv.2022.108005

Gene and cell therapies are widely recognized as future cancer therapeutics but poor controllability limits their clinical applications. Optogenetics, the use of light-controlled proteins to precisely spatiotemporally regulate the activity of genes and cells, opens up new possibilities for cancer treatment. Light of specific wavelength can activate the immune response, oncolytic activity and modulate cell signaling in tumor cells non-invasively, in dosed manner, with tissue confined action and without side effects of conventional therapies. Here, we review optogenetic approaches in cancer research, their clinical potential and challenges of incorporating optogenetics in cancer therapy. We critically discuss beneficial combinations of optogenetic technologies with therapeutic nanobodies, T-cell activation and CAR-T cell approaches, genome editors and oncolytic viruses. We consider viral vectors and nanoparticles for delivering optogenetic payloads and activating light to tumors. Finally, we highlight herein the prospects for integrating optogenetics into immunotherapy as a novel, fast, reversible and safe approach to cancer treatment.